2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 10 of 624 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02988297 (ClinicalTrials.gov)	November 2022	7/12/2016	Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis	Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: RNS60;Drug: Placebo	Revalesio Corporation	NULL	Not yet recruiting	18 Years	80 Years	All	140	Phase 2	NULL
2	NCT05286372 (ClinicalTrials.gov)	April 2022	9/3/2022	An Intermediate Size Expanded Access Protocol of AMX0035 for ALS	An Intermediate Size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phe ...	Amyotrophic Lateral Sclerosis	Drug: AMX0035	Amylyx Pharmaceuticals Inc.	NULL	Available	18 Years	N/A	All			NULL
3	NCT05281484 (ClinicalTrials.gov)	April 2022	7/3/2022	Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02	A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8	Amyotrophic Lateral Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	NULL	Available	18 Years	N/A	All			United States
4	EUCTR2021-004156-42-NL (EUCTR)	10/03/2022	21/12/2021	Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS)	A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy ...	Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Code: SAR443820 INN or Proposed INN: - Other descriptive name: RA15804589, C19061501-F, DNL788 ...	Sanofi-aventis recherche & développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	261	Phase 2	France;United States;Canada;Spain;Belgium;Germany;Netherlands;United Kingdom;Japan;Italy;China;Swede ...
5	EUCTR2021-004156-42-ES (EUCTR)	08/03/2022	30/12/2021	Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS)	A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy ...	Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Code: SAR443820 INN or Proposed INN: SAR443820 Other descriptive name: RA15804589, C19061501-F ...	Sanofi-aventis recherche & développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	261	Phase 2	France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom;Japan;Italy;China;Swede ...
6	EUCTR2021-004156-42-BE (EUCTR)	23/02/2022	22/12/2021	Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS)	A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy ...	Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Code: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489	Sanofi-aventis recherche & développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	261	Phase 2	France;United States;Canada;Spain;Belgium;Netherlands;Germany;United Kingdom;Japan;Italy;China;Swede ...
7	EUCTR2020-003376-40-SE (EUCTR)	23/02/2022	29/12/2021	A study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclero ...	A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and sa ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Edaravone Product Code: FAB122 INN or Proposed INN: EDARAVONE	Ferrer Internacional, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	France;Portugal;Spain;Poland;Belgium;Ireland;Russian Federation;Netherlands;Germany;United Kingdom;I ...
8	JPRN-jRCT2071210117	23/02/2022	21/01/2022	Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS	A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy ...	Amyotrophic Lateral Sclerosis	- Oral edaravoneadministered once daily for up to 48 weeks or until the drug is commercially availab ...	Kondo Kazuoki	NULL	Recruiting	>= 18age old	Not applicable	Both	300	Phase 3	US;Canada;Germany;Italia;South Korea;Switzerland;Japan
9	EUCTR2021-000250-26-PL (EUCTR)	23/02/2022	22/11/2021	A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Scler ...	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety ...	ALS(amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: ...	Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other ...	Amylyx Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United States;Portugal;France;Spain;Belgium;Poland;Ireland;Netherlands;Germany;United Kingdom;Italy; ...
10	EUCTR2019-001862-13-PT (EUCTR)	18/02/2022	21/05/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ...	patients suffering from Amyotrophic Lateral Sclerosis(ALS) MedDRA version: 21.1;Level: PT;Classifica ...	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive n ...	ABScience	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Greece;Spain;Ireland;Israel;Russian Federation;United Kingdom;Italy; ...

First Previous1 2 3 4 5…63Next Last